摘要
目的观察多西他赛联合顺铂治疗老年晚期非小细胞肺癌的临床疗效及毒副反应。方法对37例老年晚期非小细胞肺癌患者采用多西他赛联合顺铂方案化疗。即：第一天多西他赛75mg／m^2静脉滴注，顺铂30mg／m^2静脉滴注第1-3d，每3周重复，至少治疗2周期。结果共完成113个化疗周期，有效率40．5％，中位生存期9．4个月。主要毒副反应为骨髓抑制，发生率81％，其中，Ⅲ-Ⅳ度占8．1％。结论多西他赛联合顺铂治疗老年晚期非小细胞肺癌有较好疗效，毒副反应较小，耐受性好。
Objective： To observe the therapeutic effects and the toxic side effect of docetaxel plus cisplation in the treatment of advanced non-small cell lung cancer （NSCLC） in the elderly patients. Methods：. 37 patients with advanced NSCLC were treated with docetaxel （75mg/m^2） by intravenous infusion on 1st, 2nd, and 3rd days in a 3-week cycle. Each patient was treated at least for 2 cycles. Results： 113 cycles were finished, the effective rate was 40.5%, the median survival time was 9.4 months. The main toxic side effect was arrest of bone marrow, the incidence rate was 81% （8.1% for grade Ⅲ-Ⅳ） . conclusion： The combination of docetaxel and cisplation is effective, hypotoxic and well-tolerated in the treatment of advanced NSCLC in the elderly patients.
关键词
多西他赛
顺铂
老年
非小细胞肺癌
docetaxel cisplation the elderly non-small cell lung cancer （NSCLC）
